Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

KURA - Kura Oncology Inc


IEX Last Trade
21.08
0.570   2.704%

Share volume: 377,694
Last Updated: Fri 30 Aug 2024 10:00:00 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$20.51
0.57
2.78%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
24%
Profitability 25%
Dept financing 2%
Liquidity 50%
Performance 23%
Company vs Stock growth
vs
Performance
5 Days
4.36%
1 Month
1.74%
3 Months
1.79%
6 Months
-1.50%
1 Year
108.72%
2 Year
51.51%
Key data
Stock price
$21.08
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$7.41 - $24.17
52 WEEK CHANGE
$1.09
MARKET CAP 
1.614 B
YIELD 
N/A
SHARES OUTSTANDING 
76.634 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
BETA 
1.44
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$332,171
AVERAGE 30 VOLUME 
$579,520
Company detail
CEO: Troy Wilson
Region: US
Website: https://www.kuraoncology.com/
Employees: 146
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

at kura oncology, we are committed to realizing the promise of precision medicines for cancer. the genomics revolution is transforming how we treat cancer. we now understand that how a patient responds to treatment depends in part on the genetic makeup of the cancer and, importantly, we have the knowledge and tools to create targeted treatments and companion diagnostics to identify those patients most likely to benefit. this new era offers the potential for innovative treatments that are safer and more effective for patients with particular cancers. we are leveraging our insights into cancer genetics as well as our core strength of translating novel science into life-saving medicines to advance a pipeline of precision medicines. our development programs target cancers with high unmet need, including lung, colorectal, thyroid and pancreatic cancers as well as blood cancers such as lymphoma and leukemias. our goal is to help patients with cancer lead better, longer lives.

Recent news